Germline BRCA2 Mutations Linked to Pediatric Lymphomas
Survivors of NHL should be offered genetic counseling.
Ovarian Cancer
Pain Associated With Quality of Life and Survival for Patients With Recurrent Ovarian Cancer
Researchers sought to analyze how pain management affects quality of life and overall survival for patients with recurrent ovarian cancer.
Focus on Ovarian Cancer Surgical Volume May Not Be Best Metric
Minimum-volume standards could restrict care at many centers with better-than-expected outcomes.
Zejula Gets Priority Review for Late Stage Ovarian Cancer Indication
The sNDA is supported by data from the multicenter phase 2 QUADRA trial that evaluated the safety and activity of Zejula in 463 patients.
Ovarian Cancer Treatment Regimens
Access a detailed treatment regimen chart for ovarian cancer, with a focus on primary chemotherapy/primary adjuvant therapy with IV and IP options.
Efficacy and Safety of Olaparib Maintenance Therapy in Platinum-sensitive Ovarian Cancer Patients With BRCA Mutations: A Meta-Analysis on Randomized Controlled Trials
[Cancer Management and Research] A meta-analysis of randomized controlled trials sought to confirm the effectiveness and safety of olaparib for the treatment of relapsed BRCA-mutated ovarian cancer.
Intraperitoneal Chemotherapy Fails to Improve Outcomes in Advanced Ovarian Carcinoma
When paired with bevacizumab, neither intraperitoneal delivery of carboplatin nor cisplatin improved outcomes for patients with advanced ovarian carcinoma compared with intravenous delivery.
Mirvetuximab Soravtansine Data Lacking for FDA’s Accelerated Approval in Ovarian CA
The Food and Drug Administration (FDA) has recommended that ImmunoGen, Inc. conduct a new phase 3 randomized trial to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) in patients with high folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer.
Late-Line Niraparib in Advanced Ovarian Cancer: A Continuum of Clinical Benefit in Subgroups Characterized by Clinical and Molecular Biomarkers
More accurate biomarkers are needed to better define subgroups of patients with ovarian cancer who are most likely to benefit from late-line niraparib.
ePRO Tool Improves Symptom Management in an Outpatient Gynecologic Cancer Clinic
Investigators sought to determine if electronic patient-reported outcome tools with the PROMIS network improved identifying patients with severe symptoms and increased referrals to ancillary support services.
Next post in Gynecologic Cancer
